In this article, we will list the 5 Most Promising Mid-Cap Healthcare Stocks According to Hedge Funds. Please visit 10 Most Promising Mid-Cap Healthcare Stocks According to Hedge Funds if you’d like to see an extended list and the methodology behind it.
5. Praxis Precision Medicines Inc. (NASDAQ:PRAX)
Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds.
On June 2, Praxis Precision Medicines Inc. (NASDAQ:PRAX) published the findings of its extensive Phase 2/3 POWER1 study. This research evaluated the effectiveness of vormatrigine as a treatment for individuals with focal onset seizures. This study comes after a thorough double-blind, placebo-controlled examination that tracked patients using up to three approved anti-seizure drugs at the same time.
Monkey Business Images/Shutterstock.com
The company has emphasized very positive effectiveness signs within the higher dose group, even if the major intended goals involving substantial reductions in monthly seizure frequency were not met. Throughout the study period, the fundamental clinical data showed a strong overall safety profile and remarkably low patient discontinuation rates.
The company states that it will carefully examine these basic trial parameters to identify the best course of action for the current POWER2 research, as well as the further development of this particular drug. In the meantime, management stressed that the company is still very much committed to carrying out the planned commercial launches of ulixacaltamide and relutrigine in order to enhance its growing product portfolio.
Praxis Precision Medicines Inc. (NASDAQ:PRAX) is involved in developing therapies to cure disorders related to the central nervous system, which are characterized by neuronal excitation-inhibition imbalance. These disorders include epilepsy, movement disorders, and depression. The company utilizes its proprietary platforms like Cerebrum and Solidus to target such imbalances.
4. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds.
On May 21, Cantor Fitzgerald analyst Kristen Kluska maintained an Overweight rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and raised the price target from $84 to $96. This valuation adjustment is based on the growing institutional confidence in the underlying investment case for GTX-102, which is used to treat Angelman syndrome.
Due to highly favorable testing parameters, Kluska says that the clinical asset now shows a significantly higher likelihood of eventual success. This optimistic assessment is heavily driven by the specific structural design of its Phase 3 trial. Specifically, the comprehensive evaluation utilizes the Bayley-4 cognitive raw score alongside the MDRI metric to measure efficacy.
By organizing the clinical architecture in this manner, it can successfully establish two entirely independent pathways to achieve formal statistical success, thereby mitigating developmental risk and strengthening the broader product portfolio.
On May 8, the price target on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) was reduced by Wedbush from $27 to $26, which still yields almost 14% upside at the current level. The firm maintained a Neutral rating on the stock. Although the revenue underperformance is upsetting, management reaffirmed all aspects of the financial year 2026 revenue projection. The firm also anticipates that Crysvita will correct its course during the rest of the year.
Wedbush also expects the company to turn profitable sometime in 2027. Predominantly, Ultragenyx has two PDUFAs for DTX401 and UX111, both of which offer a chance for profitable PRVs, while Wedbush is awaiting Phase 3 ASPIRE results for GTX102.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) develops novel therapies, with a focus on identifying, acquiring, and commercializing products for rare and ultra-rare genetic diseases. It has a strong emphasis on gene therapy and covers various stages of clinical trials. The company is currently going through high cash burn with the aim of turning profitable from 2027 onwards.
3. Nektar Therapeutics (NASDAQ:NKTR)
Nektar Therapeutics (NASDAQ:NKTR) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds.
On May 11, Wedbush analyst Martin Fan decreased the price target on Nektar Therapeutics (NASDAQ:NKTR) from $95 to $80 while reiterating a Neutral rating. This revision is followed by the recent corporate earnings report, where Nektar has reaffirmed forward-looking guidance across its broader product portfolio.
Additionally, the company has confirmed that by July 2026, it will be initiating the Phase 3 ZENITH-AD program for rezpegaldesleukin, which is used to treat atopic dermatitis. Despite this clinical progression, the analyst is still quite uncertain about the possibility of significant first-line market penetration.
Fan believes that Dupixent’s well-established commercial dominance is a major factor in this cautious approach. Furthermore, within two years of any prospective rezpegaldesleukin launch alternative biosimilars are expected to enter the market, posing a threat to the competitive environment.
On May 8, while retaining an Overweight rating on the stock, Yasmeen Rahimi from Piper Sandler increased the firm’s price target on Nektar Therapeutics (NASDAQ:NKTR) from $105 to $192. The adjustments lead to a highly lucrative upside potential of over 200% at the prevailing level.
The firm noted that Nektar disclosed its first quarter results and provided an update on REZPEG’s Phase 3 ZENITH-AD program design, which will comprise five trials in total. The two biologic-naive AD studies will begin in July 2026, and the first ZENITH-AD readout will occur in mid-2028. Additionally, a third trial with AD patients with biologic experience is included in ZENITH-AD, with commencement taking place some months after biologic naive.
Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company that discovers and develops drugs targeting immunological dysfunctions. It develops rezpegaldesleukin, NKTR-0165, NKTR-0166, NKTR-422, and NKTR-255. These are used to treat autoimmune disorders, ulcerative colitis, and multiple sclerosis, autoimmune diseases, fibrotic diseases, and solid tumors/large B-cell lymphoma, respectively.
2. Acadia Healthcare Company Inc. (NASDAQ:ACHC)
Acadia Healthcare Company Inc. (NASDAQ:ACHC) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds.
On May 4, following a strong first-quarter report, Raymond James upgraded its rating on Acadia Healthcare Company, Inc. (NASDAQ:ACHC) from Outperform to Strong Buy. The firm also adjusted its price target upward from $25 to $39, resulting in an adjusted upside of more than 67%.
The firm noted that Acadia modestly increased its 2026 earnings and EBITDA guidance. It believes that the company is well-positioned for estimate revisions and elevated valuation multiples, as it works to extract a $200 million target from underperforming locations while maintaining a modest growth trajectory.
On May 1, Cantor Fitzgerald increased the target price on Acadia Healthcare Company Inc. (NASDAQ:ACHC) from $20 to $30, while reiterating a Neutral rating on the shares. This yields a revised upside potential of roughly 29% at the prevailing level.
According to an investor brief reported by the firm, escalating bad debt and denial patterns are neutralizing operational improvements. Although concentrated among specific insurance providers and regions, these trends continue to create ambiguity around the short-term outlook despite some positive core operational performance.
Acadia Healthcare Company Inc. (NASDAQ:ACHC) provides behavioral healthcare services in the U.S. and Puerto Rico. The company runs various facilities, including acute inpatient psychiatric centers, residential recovery and eating disorder facilities, comprehensive treatment centers, and residential treatment centers. It also facilitates outpatient behavioral healthcare services addressing the mental health and recovery needs of communities.
1. Dianthus Therapeutics Inc. (NASDAQ:DNTH)
Dianthus Therapeutics Inc. (NASDAQ:DNTH) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds.
On May 7, Raymond James increased its price target on Dianthus Therapeutics Inc. (NASDAQ:DNTH) from $123 to $125. The firm also reiterated its Strong Buy rating on the stock, which currently yields a revised upside potential of nearly 40%.
The company’s first quarter update showed a lot of progress with its drug pipeline, which included an orphan drug designation for its claseprubart program. The company is also prioritizing DNTH212, which is backed by the dual BDCA2 and BAFF/APRIL procedures.
Raymond James also made note of potential short-term catalysts for the company expected during 2026. These include Phase 1 data along with Phase 2 results for MMN expected during the final quarter. The company also aims to begin the Phase 3 study during mid-year, with a potential topline impact expected sometime in 2028.
On May 5, Dianthus Therapeutics Inc. (NASDAQ:DNTH) shared progress around the development of a rheumatology franchise with DNTH212 and moving claseprubart through critical trials in neuromuscular illnesses. The company is establishing itself as a pioneer in autoimmune disease treatments. Although the success will depend on providing solid clinical results across several categories, the $719 million financing offers considerable financial flexibility.
It is important to note that targeted treatments for severe and uncommon autoimmune diseases are becoming increasingly important in the biotech industry, and Dianthus’s pipeline may set it apart in an increasingly competitive marketplace.
Dianthus Therapeutics Inc. (NASDAQ:DNTH) is a clinical-stage biotechnology company that develops therapies for patients with severe autoimmune diseases. Its lead candidate, claseprubart, is a monoclonal antibody that blocks the C1s protein to stop immune overactivation effectively. The second one is DNTH212, which reduces interferon production and suppresses B-cell activity simultaneously.
While we acknowledge the potential of DNTH to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than DNTH and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 12 Oversold Financial Stocks to Invest in According to Hedge Funds.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
